Teva, Novartis End Patent Spat Over Zometa
A judge has dismissed a patent infringement suit between Teva Pharmaceuticals Industries Ltd. and Novartis Corp. over a generic version of the Swiss drugmaker's bone treatment Zometa....To view the full article, register now.
Already a subscriber? Click here to view full article